InnoCare Pharma ($諾誠健華(09969.HK)$;$諾誠健華-U(688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor...
InnoCare Pharma ($諾誠健華(09969.HK)$;$諾誠健華-U(688428.SH)$), a commercial-stage biotech company, announced today that the latest data of the novel TYK2 inhibitor ICP-332 developed by the Company for the treatment of patients with moderate-to-severe atopic dermatitis (AD) has been released at the 2024 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral ...
InnoCare Pharma's balance sheet indicates it can handle adversity with more cash than debt. Despite an EBIT loss last year, solid revenue growth may suggest a path to profitability.
InnoCare Pharma ($諾誠健華(09969.HK)$;$諾誠健華-U(688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient has been dosed in clinical trial with its second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University Cancer Center. This is the first time that zurletrec...
InnoCare ($諾誠健華(09969.HK)$;$諾誠健華-U(688428.SH)$) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been recently approved by the Medical Products Administration of Guangdong Province, under the early access program in Guangdong-Hong Kong-Macao Greater Bay Area (“Gre...
InnoCare Pharma ($諾誠健華(09969.HK)$;$諾誠健華-U(688428.SH)$), a commercial-stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company's B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. This is InnoCare’s fifth innovative drug to enter the clinical stage in the U.S. This is a Phase I study to evaluate the...
InnoCare Pharma ($諾誠健華(09969.HK)$$諾誠健華-U(688428.SH)$) announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S. Pacific Standard Time (00:30 AM, January 11, 2023, Beijing Time), to update the Company’s latest development. The J.P. Morgan Healthcare Conference is the most influential event for the...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer (CFO). He reports to the Co-founder, Chairwoman and CEO of InnoCare Pharma, Dr. Jasmine Cui. Mr. Fu is responsible for the Company’s growth strategy, financial management, investment & financin...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that phase II clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis (AD). ICP-332 in AD patients treated for 4 weeks...
諾誠健華股票討論區
This is a Phase I study to evaluate the...
The J.P. Morgan Healthcare Conference is the most influential event for the...
ICP-332 in AD patients treated for 4 weeks...
暫無評論